Markgren PO - Search Results

1

Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418.

Bhat R, Xue Y, Berg S, Hellberg S, Ormö M, Nilsson Y, Radesäter AC, Jerning E, Markgren PO, Borgegård T, Nylöf M, Giménez-Cassina A, Hernández F, Lucas JJ, Díaz-Nido J, Avila J. Bhat R, et al. Among authors: markgren po. J Biol Chem. 2003 Nov 14;278(46):45937-45. doi: 10.1074/jbc.M306268200. Epub 2003 Aug 19. J Biol Chem. 2003. PMID: 12928438 Free article.

2

2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation.

Tidén AK, Sjögren T, Svensson M, Bernlind A, Senthilmohan R, Auchère F, Norman H, Markgren PO, Gustavsson S, Schmidt S, Lundquist S, Forbes LV, Magon NJ, Paton LN, Jameson GN, Eriksson H, Kettle AJ. Tidén AK, et al. Among authors: markgren po. J Biol Chem. 2011 Oct 28;286(43):37578-89. doi: 10.1074/jbc.M111.266981. Epub 2011 Aug 31. J Biol Chem. 2011. PMID: 21880720 Free PMC article.

3

Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.

Alterman M, Björsne M, Mühlman A, Classon B, Kvarnström I, Danielson H, Markgren PO, Nillroth U, Unge T, Hallberg A, Samuelsson B. Alterman M, et al. Among authors: markgren po. J Med Chem. 1998 Sep 24;41(20):3782-92. doi: 10.1021/jm970777b. J Med Chem. 1998. PMID: 9748353

4

Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.

Markgren PO, Schaal W, Hämäläinen M, Karlén A, Hallberg A, Samuelsson B, Danielson UH. Markgren PO, et al. J Med Chem. 2002 Dec 5;45(25):5430-9. doi: 10.1021/jm0208370. J Med Chem. 2002. PMID: 12459011

5

Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs.

Nillroth U, Vrang L, Markgren PO, Hultén J, Hallberg A, Danielson UH. Nillroth U, et al. Among authors: markgren po. Antimicrob Agents Chemother. 1997 Nov;41(11):2383-8. doi: 10.1128/AAC.41.11.2383. Antimicrob Agents Chemother. 1997. PMID: 9371337 Free PMC article.

6

Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants.

Shuman CF, Markgren PO, Hämäläinen M, Danielson UH. Shuman CF, et al. Among authors: markgren po. Antiviral Res. 2003 May;58(3):235-42. doi: 10.1016/s0166-3542(03)00002-0. Antiviral Res. 2003. PMID: 12767471

7

Screening of compounds interacting with HIV-1 proteinase using optical biosensor technology.

Markgren PO, Hämäläinen M, Danielson UH. Markgren PO, et al. Anal Biochem. 1998 Dec 15;265(2):340-50. doi: 10.1006/abio.1998.2927. Anal Biochem. 1998. PMID: 9882412

8

Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology.

Markgren PO, Hämäläinen M, Danielson UH. Markgren PO, et al. Anal Biochem. 2000 Mar 1;279(1):71-8. doi: 10.1006/abio.1999.4467. Anal Biochem. 2000. PMID: 10683232

9

Characterization of a set of HIV-1 protease inhibitors using binding kinetics data from a biosensor-based screen.

Hämäläinen MD, Markgren PO, Schaal W, Karlén A, Classon B, Vrang L, Samuelsson B, Hallberg A, Danielson UH. Hämäläinen MD, et al. Among authors: markgren po. J Biomol Screen. 2000 Oct;5(5):353-60. doi: 10.1177/108705710000500507. J Biomol Screen. 2000. PMID: 11080694

10

P1/P1' modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays.

Alterman M, Sjöbom H, Säfsten P, Markgren PO, Danielson UH, Hämäläinen M, Löfås S, Hultén J, Classon B, Samuelsson B, Hallberg A. Alterman M, et al. Among authors: markgren po. Eur J Pharm Sci. 2001 May;13(2):203-12. doi: 10.1016/s0928-0987(01)00109-9. Eur J Pharm Sci. 2001. PMID: 11297905

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page